Two cases of Alzheimer's disease showing deterioration of behavioral and psychological symptoms of dementia induced by switching from rivastigmine to donepezil

Takemi Kimura, Junichi TakamatsuDivision of Clinical Research, National Hospital Organization Kikuchi Hospital, Koshi, Kumamoto, JapanAbstract: Rivastigmine, galantamine, and memantine, in addition to donepezil, which has been on the market over 10 years, have been available for the treatment of Alz...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Kimura T, Takamatsu J
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2012
Materias:
Acceso en línea:https://doaj.org/article/f3a5d771b03c42fa919bc47881f74f4d
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:f3a5d771b03c42fa919bc47881f74f4d
record_format dspace
spelling oai:doaj.org-article:f3a5d771b03c42fa919bc47881f74f4d2021-12-02T03:58:43ZTwo cases of Alzheimer's disease showing deterioration of behavioral and psychological symptoms of dementia induced by switching from rivastigmine to donepezil1176-63281178-2021https://doaj.org/article/f3a5d771b03c42fa919bc47881f74f4d2012-12-01T00:00:00Zhttp://www.dovepress.com/two-cases-of-alzheimer39s-disease-showing-deterioration-of-behavioral--a11841https://doaj.org/toc/1176-6328https://doaj.org/toc/1178-2021Takemi Kimura, Junichi TakamatsuDivision of Clinical Research, National Hospital Organization Kikuchi Hospital, Koshi, Kumamoto, JapanAbstract: Rivastigmine, galantamine, and memantine, in addition to donepezil, which has been on the market over 10 years, have been available for the treatment of Alzheimer's disease (AD) since 2011 in Japan, leading a new stage in the medical treatment of AD. We studied two AD patients showing sudden deterioration of behavioral and psychological symptoms of dementia (BPSD) associated with switching from rivastigmine to donepezil after the clinical trial of rivastigmine. In the patients, rivastigmine seemed to be more beneficial than donepezil for the control of BPSD. Although It was not obvious whether their different responses to the two cholinesterase inhibitors were due to the different pharmacological profiles, ie, the presence of inhibition of butyrylcholinesterase in rivastigmine, a particular cholinesterase inhibitor might be more effective in particular AD cases. Further investigations are needed to confirm the difference, and to identify the measures for selecting the most appropriate medication for each AD patient.Keywords: rivastigmine, donepezil, cholinesterase inhibitors, switching, behavioral and psychological symptoms of dementia, neuropsychiatric inventory, Japanese, Alzheimer's diseaseKimura TTakamatsu JDove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2013, Iss default, Pp 49-53 (2012)
institution DOAJ
collection DOAJ
language EN
topic Neurosciences. Biological psychiatry. Neuropsychiatry
RC321-571
Neurology. Diseases of the nervous system
RC346-429
spellingShingle Neurosciences. Biological psychiatry. Neuropsychiatry
RC321-571
Neurology. Diseases of the nervous system
RC346-429
Kimura T
Takamatsu J
Two cases of Alzheimer's disease showing deterioration of behavioral and psychological symptoms of dementia induced by switching from rivastigmine to donepezil
description Takemi Kimura, Junichi TakamatsuDivision of Clinical Research, National Hospital Organization Kikuchi Hospital, Koshi, Kumamoto, JapanAbstract: Rivastigmine, galantamine, and memantine, in addition to donepezil, which has been on the market over 10 years, have been available for the treatment of Alzheimer's disease (AD) since 2011 in Japan, leading a new stage in the medical treatment of AD. We studied two AD patients showing sudden deterioration of behavioral and psychological symptoms of dementia (BPSD) associated with switching from rivastigmine to donepezil after the clinical trial of rivastigmine. In the patients, rivastigmine seemed to be more beneficial than donepezil for the control of BPSD. Although It was not obvious whether their different responses to the two cholinesterase inhibitors were due to the different pharmacological profiles, ie, the presence of inhibition of butyrylcholinesterase in rivastigmine, a particular cholinesterase inhibitor might be more effective in particular AD cases. Further investigations are needed to confirm the difference, and to identify the measures for selecting the most appropriate medication for each AD patient.Keywords: rivastigmine, donepezil, cholinesterase inhibitors, switching, behavioral and psychological symptoms of dementia, neuropsychiatric inventory, Japanese, Alzheimer's disease
format article
author Kimura T
Takamatsu J
author_facet Kimura T
Takamatsu J
author_sort Kimura T
title Two cases of Alzheimer's disease showing deterioration of behavioral and psychological symptoms of dementia induced by switching from rivastigmine to donepezil
title_short Two cases of Alzheimer's disease showing deterioration of behavioral and psychological symptoms of dementia induced by switching from rivastigmine to donepezil
title_full Two cases of Alzheimer's disease showing deterioration of behavioral and psychological symptoms of dementia induced by switching from rivastigmine to donepezil
title_fullStr Two cases of Alzheimer's disease showing deterioration of behavioral and psychological symptoms of dementia induced by switching from rivastigmine to donepezil
title_full_unstemmed Two cases of Alzheimer's disease showing deterioration of behavioral and psychological symptoms of dementia induced by switching from rivastigmine to donepezil
title_sort two cases of alzheimer's disease showing deterioration of behavioral and psychological symptoms of dementia induced by switching from rivastigmine to donepezil
publisher Dove Medical Press
publishDate 2012
url https://doaj.org/article/f3a5d771b03c42fa919bc47881f74f4d
work_keys_str_mv AT kimurat twocasesofalzheimeramp39sdiseaseshowingdeteriorationofbehavioralandpsychologicalsymptomsofdementiainducedbyswitchingfromrivastigminetodonepezil
AT takamatsuj twocasesofalzheimeramp39sdiseaseshowingdeteriorationofbehavioralandpsychologicalsymptomsofdementiainducedbyswitchingfromrivastigminetodonepezil
_version_ 1718401527139270656